An observational study in Heart Failure, sponsored by Hospital do Coracao. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Hospital do Coracao · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BREATHE III is a prospective, multicenter, observational registry designed to provide contemporary insights into the epidemiological, clinical, and prognostic characteristics of patients hospitalized with acute heart failure (AHF) in Brazil, including those with decompensated heart failure or new-onset ventricular dysfunction during acute myocardial infarction.
Recent evidence, such as the STRONG-HF trial, has demonstrated the prognostic benefit of rapid initiation and up-titration of guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF). However, prior phases of the BREATHE registry did not evaluate the timing of therapeutic optimization or barriers to implementing these strategies. Additionally, the therapeutic landscape of heart failure has evolved substantially in recent years, with the introduction of novel pharmacological agents, expanded indications for existing therapies, and new treatment options for heart failure with preserved ejection fraction (HFpEF).
BREATHE III aims to address these knowledge gaps by systematically assessing, over a 12-month follow-up, patient characteristics, treatment patterns, adherence to guideline-recommended therapies, time to treatment optimization, and clinical outcomes. The study will also identify barriers to the implementation and titration of evidence-based therapies, evaluate regional variations in care, and describe contemporary management practices across public and private healthcare settings in Brazil.
The results of this registry are expected to inform strategies to improve quality of care, optimize resource allocation, and guide future interventions aimed at reducing morbidity and mortality associated with heart failure in Brazil.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 200 across 1,987 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study will include adult patients (≥18 years) admitted to public and private hospitals in Brazil with acute heart failure-related presentations. Eligible participants comprise two main groups: (1) patients hospitalized for acute myocardial infarction (AMI) who develop newly identified left ventricular systolic dysfunction during hospitalization (LVEF ≤40), limited to up to 25% of the total study population; and (2) patients admitted with a primary diagnosis of decompensated heart failure, regardless of ejection fraction, defined according to the universal criteria for heart failure. In patients with heart failure with preserved ejection fraction (HFpEF), additional characterization will include H2FPEF and HFA-PEFF scores.
Patients will be excluded if they decline participation during the informed consent process, have undergone surgical myocardial revascularization within the previous month, present with heart failure secondary to sepsis, or are admitted with cardiogenic shock.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult patients (≥ 18 years) admitted to public and private hospitals with one of the two clinical conditions below:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All-cause mortality
All cases of death
Time frame: 12 months
Length of hospital stay
Duration of hospitalization
Time frame: 12 months
Composite outcome of death and rehospitalization
Death or new hospitalization during follow-up
Time frame: 12 months
General rehospitalization, rehospitalization due to heart failure and emergency visits
All-cause of rehospitalization, rehospitalization due to heart failure and emergency visits
Time frame: 12 months
Cardiovascular death
Death due to cardiovascular causes
Time frame: 12 months
Composite outcome of cardiovascular death and rehospitalization due to heart failure
Death to cardiovascular cause or rehospitalization due to heart failure
Time frame: 12 months
Proportion of patients receiving interventions with proven benefit demonstrated by different indicators of quality of care (at target dose)
Percentage of patients receiving guideline-directed therapies
Time frame: 12 months
Quality of life according to the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Assessment of Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Time frame: 12 months
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Apr 2026; primary completion for Oct 2028, 29 months later.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 29 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital do Coracao